184 related articles for article (PubMed ID: 36203199)
21. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
22. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
[TBL] [Abstract][Full Text] [Related]
23. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
[TBL] [Abstract][Full Text] [Related]
24. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
[TBL] [Abstract][Full Text] [Related]
25. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
[TBL] [Abstract][Full Text] [Related]
26. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
Lopez-Rios F; Angulo B; Gomez B; Mair D; Martinez R; Conde E; Shieh F; Tsai J; Vaks J; Current R; Lawrence HJ; Gonzalez de Castro D
J Clin Pathol; 2013 May; 66(5):381-5. PubMed ID: 23386666
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
28. Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Uchibori K; Takano N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Sakamoto H; Yoshida H; Amino Y; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2021 Mar; 12(6):906-913. PubMed ID: 33528892
[TBL] [Abstract][Full Text] [Related]
29. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer.
Mizote S; Matsumura M; Sekiya M; Sugiyama M; Sekine A; Kobayashi N; Kataoka T; Iwashita H; Okudela K
Cancer Treat Res Commun; 2022; 32():100614. PubMed ID: 35878517
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the Analytical Performance Between cobas EGFR Assay and PCR-Clamp Method in the Detection of EGFR Mutations in Japanese Non-Small Cell Lung Cancer Patients.
Ai T; Yuri M; Tabe Y; Kakimoto A; Morishita S; Tsuchiya K; Takamochi K; Kodama Y; Takahashi F; Shigeki M; Horii T; Suzuki K; Takahashi K; Miida T; Ohsaka A
Clin Lab; 2017 May; 63(5):1021-1026. PubMed ID: 28627833
[TBL] [Abstract][Full Text] [Related]
31. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
[TBL] [Abstract][Full Text] [Related]
33. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
34. EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Dearden S; Brown H; Jenkins S; Thress KS; Cantarini M; Cole R; Ranson M; Jänne PA
Lung Cancer; 2017 Jul; 109():9-13. PubMed ID: 28577957
[TBL] [Abstract][Full Text] [Related]
35. Detection of
Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
[TBL] [Abstract][Full Text] [Related]
36. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).
Heeke S; Benzaquen J; Hofman V; Ilié M; Allegra M; Long-Mira E; Lassalle S; Tanga V; Salacroup C; Bonnetaud C; Fayada J; Gazoppi L; Ribeyre L; Castelnau O; Garnier G; Cattet F; Nanni I; de Fraipont F; Cohen C; Berthet JP; Leroy S; Poudenx M; Marquette CH; Denis MG; Barlesi F; Hofman P
Clin Lung Cancer; 2020 Jan; 21(1):56-65.e8. PubMed ID: 31519454
[TBL] [Abstract][Full Text] [Related]
37. Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer.
Park IH; Son DS; Choi YL; Choi JH; Park JE; Jeon YJ; Cho M; Kim HK; Choi YS; Shim YM; Kang JH; Park S; Lee J; Kim SH; Lee BC; Kim J
Cancer Res Treat; 2024 Jan; 56(1):81-91. PubMed ID: 37340844
[TBL] [Abstract][Full Text] [Related]
38. Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods.
Matsubara T; Nakajima E; Namikawa H; Ono S; Takada I; Ohira T; Morishita Y; Miyazaki T; Furukawa K; Ikeda N
Mol Clin Oncol; 2022 Jan; 16(1):15. PubMed ID: 34881035
[TBL] [Abstract][Full Text] [Related]
39. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).
Ramadhan HH; Taaban DF; Hassan JK
Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678
[TBL] [Abstract][Full Text] [Related]
40. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
